PDCD1 and breast cancer: In the past decade, clinical immunotherapy of BC has achieved great advances with the advent of immune checkpoint inhibitors, including inhibitors targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) (16).